Lung cancer is one of the leading causes of death world-wide with the majority of patients suffering from advanced unresectable or metastatic non-small cell lung cancer. Despite the advances in palliative chemotherapy, the survival rate for patients with this advanced disease treated with chemotherapy remains poor. In this book, the authors present topical research in the study of lung cancer treatments including epidermal growth factor tyrosine kinase inhibitors, in the management of advanced stage non-small cell lung cancer; lung cancer brachytherapy; volumetric modulated arc therapy and future individualised therapy for lung cancer in post-genomic era.